Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: EyeDrMike who wrote (5846)	3/9/1998 9:39:00 PM
From: IRA ZOHN	Respond to of 23519

Finkelstein, Thompson & Loughran Announces Securities Class Action Against Zonagen, Inc. WASHINGTON, March 9 /PRNewswire/ -- Finkelstein, Thompson & Loughran hereby gives notice that a Class Action Complaint was filed today in the United States District Court for the Southern District of Texas under the caption James M. Nathenson v. Zonagen, Inc. et al., alleging violations of the Securities Exchange Act of 1934 (''the Exchange Act''). Plaintiff seeks to represent a class of persons who purchased the common stock of Zonagen, Inc. (Nasdaq: ZONA - news; ''Zonagen'' or ''the Company'') between April 1, 1996 and November 18, 1997, inclusive. The Complaint names Zonagen and certain of the Company's officers and directors as defendants, alleging that these parties violated Sections 10(b) and 20(a) of the Exchange Act, as well as SEC Rule 10b-5 promulgated thereunder, by originating a series of materially misleading statements and omissions concerning the Company's business prospects and its intellectual property rights with regard to its purported impotency drug, Vasomax, and a purportedly proprietary adjuvant, which the defendants called ImmuMax. Specifically, Plaintiff alleges that the defendants misrepresented the patent protection which the Company enjoyed with respect to Vasomax, and misrepresented that the Company had developed a new adjuvant, ImmuMax, when this compound was actually a previously patented adjuvant called Chitosan. On November 18, 1997, a third party issued a press release revealing that Zonagen did not have patent protection for its Vasomax product. This disclosure, and subsequent disclosures concerning the Company's products and intellectual property rights sent Zonagen's share prices plummeting, from a Class Period high of $44 1/8 on October 13, 1997 to a low of $14 15/16 on January 12, 1998. Plaintiff seeks to recover damages on behalf of all investors who purchased Zonagen stock during the Class Period, and are represented by the law firm of Finkelstein, Thompson & Loughran, of Washington, DC, among others. This firm has broad experience in representing defrauded investors in shareholder class actions, has been appointed to lead positions in many such actions, and has over 30 years of securities litigation experience in federal and state courts throughout the United States. If you are a member of the Class described above, and if you meet certain other legal requirements, you may, not later than 60 days from today, move the Court to serve as a lead plaintiff. If you wish to discuss this action or have any questions concerning this notice or your rights or interests, please contact Donald J. Enright with Finkelstein, Thompson & Loughran, toll-free at (888) 333-4409, or at (202) 337-8000. If you wish to learn more about Finkelstein, Thompson & Loughran, you can visit their Web page at www.ftllaw.com. SOURCE: Finkelstein, Thompson & Loughran